(Q37079120)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18257611%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

review article

1 reference

title

Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18257611%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18257611%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Diane M Harper

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18257611%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

publication date

1 January 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18257611%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18257611%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

68

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18257611%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18257611%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

359-372

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18257611%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003495-200868030-00007

2 January 2020

exact match

0 references

cites work

Cervical human papillomavirus screening among older women

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200868030-00007

Carcinogenicity of human papillomaviruses

21 January 2018

1 reference

12 December 2020

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

1 reference

12 December 2020

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

1 reference

12 December 2020

Immune responses to human papillomavirus

1 reference

12 December 2020

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only

1 reference

12 December 2020

Cost-effectiveness of HPV 16, 18 vaccination in Brazil

1 reference

12 December 2020

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

12 December 2020

The epidemiology of human papillomavirus infections

1 reference

12 December 2020

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

1 reference

12 December 2020

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

1 reference

12 December 2020

Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries

1 reference

12 December 2020

Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival.

1 reference

12 December 2020

Global cancer statistics, 2002

1 reference

12 December 2020

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine

1 reference

12 December 2020

A prophylactic hepatitis B vaccine with a novel adjuvant system

1 reference

12 December 2020

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

1 reference

12 December 2020

American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors

1 reference

12 December 2020

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

12 December 2020

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

12 December 2020

Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

1 reference

12 December 2020

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

12 December 2020

Prevalence of HPV infection among females in the United States

1 reference

12 December 2020

A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica

1 reference

12 December 2020

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

1 reference

12 December 2020

Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing

1 reference

12 December 2020

A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine

1 reference

12 December 2020

Human papillomavirus and cervical cancer

1 reference

12 December 2020

Vaccine adjuvants revisited

1 reference

12 December 2020

Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control

1 reference

12 December 2020

Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK

1 reference

12 December 2020

Cost-effectiveness analyses of human papillomavirus vaccination

1 reference

12 December 2020

Strategies for the prevention of cervical cancer by human papillomavirus vaccination.

1 reference

12 December 2020

Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening

1 reference

12 December 2020

Advances in prevention of cervical cancer and other human papillomavirus-related diseases

1 reference

12 December 2020

Chapter 6: Epidemiology and transmission dynamics of genital HPV infection

1 reference

12 December 2020

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

1 reference

12 December 2020

Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing

1 reference

12 December 2020

Chapter 2: The burden of HPV-related cancers

1 reference

12 December 2020

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

1 reference

12 December 2020

Women with atypical glandular cells: a long-term follow-up study in a high-risk population

1 reference

12 December 2020

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

1 reference

12 December 2020

Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04

1 reference

12 December 2020

Chapter 1: HPV in the etiology of human cancer

1 reference

12 December 2020

Vaccination strategies for the treatment and prevention of cervical cancer

1 reference

12 December 2020

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

1 reference

12 December 2020

Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland

1 reference

12 December 2020

Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

1 reference

12 December 2020

Role of Innate Immune Factors in the Adjuvant Activity of Monophosphoryl Lipid A

1 reference

12 December 2020

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).

1 reference

12 December 2020

Prophylactic HPV vaccines

1 reference

12 December 2020

Monophosphoryl lipid A activates both human dendritic cells and T cells

1 reference

12 December 2020

The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice.

1 reference

12 December 2020

10.2165/00003495-200868030-00007

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18257611%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference